Skip to Content
Merck
  • Nanoadjuvant-triggered STING activation evokes systemic immunotherapy for repetitive implant-related infections.

Nanoadjuvant-triggered STING activation evokes systemic immunotherapy for repetitive implant-related infections.

Bioactive materials (2024-01-29)
Dongdong Xu, Jun Hu, Jiawei Mei, Jun Zhou, Zhengxi Wang, Xudong Zhang, Quan Liu, Zheng Su, Wanbo Zhu, Hongjian Liu, Chen Zhu
ABSTRACT

Repetitive implant-related infections (IRIs) are devastating complications in orthopedic surgery, threatening implant survival and even the life of the host. Biofilms conceal bacterial-associated antigens (BAAs) and result in a "cold tumor"-like immune silent microenvironment, allowing the persistence of IRIs. To address this challenge, an iron-based covalent organic framed nanoadjuvant doped with curcumin and platinum (CFCP) was designed in the present study to achieve efficient treatment of IRIs by inducing a systemic immune response. Specifically, enhanced sonodynamic therapy (SDT) from CFCP combined with iron ion metabolic interference increased the release of bacterial-associated double-stranded DNA (dsDNA). Immunogenic dsDNA promoted dendritic cell (DC) maturation through activation of the stimulator of interferon gene (STING) and amplified the immune stimulation of neutrophils via interferon-β (IFN-β). At the same time, enhanced BAA presentation aroused humoral immunity in B and T cells, creating long-term resistance to repetitive infections. Encouragingly, CFCP served as neoadjuvant immunotherapy for sustained antibacterial protection on implants and was expected to guide clinical IRI treatment and relapse prevention.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-IFN-β antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution